MRI-Assisted Guidance for Non-Essential Tissue Sampling

Exclusion Criteria

• •History of prior prostate biopsy (to ensure baseline risk homogeneity). Prior treatment for prostate cancer or use of 5-alpha reductase inhibitors (5-ARIs) within 6 months.
• •Candidates who have explicitly opted for focal therapy prior to biopsy (where systematic mapping remains mandatory).
• •Contraindications to MRI (e.g., incompatible implants, severe renal impairment).
• •Active urinary tract infection or acute prostatitis.